Financial Report - Abbvie

Abbvie

1Q Revenues: $8.6 billion (+ 10%)
1Q Earnings: $3.0 billion (+23%)
Comments: Global HUMIRA revenues were $4.7 billion, up 6%, with U.S. revenues of $3.7 billion, an increase of 14%, and international sales of $1.0 billion, down 15% due to biosimilar competition. Global revenues from the hematologic oncology portfolio were $1.5 billion, up 32%, with IMBRUVICA revenues of $1.2 billion, up 21%. Global VENCLEXTA revenues were $317 million. SKYRIZI revenues were $300 million and RINVOQ revenues were $86 million. HCV drug Mavyret sales were down 29% to $559 million. Creon sales were $276 million, up 22%. Lupron sales were $233 million, up 2%. Synthroid sales were up 12% to $205 million. Synagis sales were down 6% to $270 million. Duodopa sales were $124 million, up 12%.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.